MONTREAL – The CEO of Valeant Pharmaceuticals International Inc. on Wednesday presented investors with a company that’s cutting earnings and purchasers forecasts, abandoning price increases, focusing on reducing debt and promoting its research and development spending. The end result: The marketplace wants it. Over the course of the Laval, Que.-based ...
Read More »